Cullinan Therapeutics Unveils Initial Clinical Data for CLN-978 at EULAR 2026

Cullinan Therapeutics presented promising initial data for CLN-978, highlighting its potential as a treatment for systemic lupus erythematosus and rheumatoid arthritis at the EULAR 2026 Congress. The findings suggest significant clinical benefits, including remissions and favorable safety profiles.